Safety and Efficacy Study of SAR442720 in Combination With Pembrolizumab in Advanced Malignancies
Status:
Recruiting
Trial end date:
2025-07-15
Target enrollment:
Participant gender:
Summary
Primary Objective:
Part 1:
- To characterize the safety and tolerability of SAR442720 in combination with
pembrolizumab in patients with advanced solid tumors including NSCLC who progressed on
anti-PD-1/PD L1 containing therapy and advanced colorectal cancer (CRC) after
progression to all standard of care (SOC) therapy.
- To define the MTD and RP2D for the combination of SAR442720 and pembrolizumab in
patients with solid tumors
Part 2:
- To determine the antitumor activity of SAR442720 in combination with pembrolizumab
Secondary Objective:
Part 1:
- To document the pharmacokinetic (PK) of SAR442720 in combination with pembrolizumab and
to document the PK of pembrolizumab in combination with SAR442720
- To estimate the anti-tumor effects of SAR442720 in combination with pembrolizumab in all
participants
Part 2:
- To assess the safety profile of SAR442720 in combination with pembrolizumab
- To assess other indicators of antitumor activity.
- To assess the pharmacokinetic (PK) of SAR442720 in combination with pembrolizumab, and
to assess the PK of pembrolizumab in combination with SAR442720